Patents by Inventor John OHD

John OHD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Base-Modified Cytidine Nucleotides for Leukemia Therapy
    Publication number: 20210261584
    Abstract: Compounds of the formula I wherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Inventors: Pedro PINHO, Björn KLASSON, John OHD, Mark ALBERTELLA
  • Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer
    Patent number: 10960017
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • SORAFENIB OR REGORAFENIB TROXACITABINE PHOSPHORAMIDATE PRODRUG COMBINATION THERAPY FOR LIVER CANCER
    Publication number: 20200009166
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 9, 2020
    Applicant: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
    Patent number: 10456413
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 29, 2019
    Assignee: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE
    Publication number: 20190091246
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Applicant: Medivir Aktiebolag
    Inventors: Mark ALBERTELLA, Anders ENEROTH, Björn KLASSON, Fredrik ÖBERG, John ÖHD